Whole genome sequencing for children An information guide for parents, carers and families, NHS England (published/updated 24th January 2023)
This guide, produced in partnership with the Children ' s Cancer and Leukaemia Group, provides information about a whole genome sequencing (WGS) test as part of a child ' s diagnosis for cancer, suspected cancer and benign tumours. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - January 25, 2023 Category: Consumer Health News Source Type: news
FDA Approves New Drug for Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
MONDAY, Jan. 23, 2023 -- The U.S. Food and Drug Administration has approved zanubrutinib (Brukinsa), a next-generation BTK inhibitor, for the treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
The approval was... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 23, 2023 Category: General Medicine Source Type: news
FDA Approves Zanubrutinib (Brukinsa) for Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
MONDAY, Jan. 23, 2023 -- The U.S. Food and Drug Administration has approved zanubrutinib (Brukinsa), a next-generation BTK inhibitor, for the treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
The approval was... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 23, 2023 Category: General Medicine Source Type: news
FDA OKs Zanubrutinib (Brukinsa) for CLL or SLL FDA OKs Zanubrutinib (Brukinsa) for CLL or SLL
The FDA granted accelerated approval to the BTK inhibitor zanubrutinib for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 20, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
FDA Greenlights BTK Inhibitor Zanubrutinib for CLL/SLL
(MedPage Today) -- The FDA has approved the Bruton's tyrosine kinase (BTK) inhibitor zanubrutinib (Brukinsa) for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Approval was based on results... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - January 20, 2023 Category: American Health Source Type: news
Brukinsa (zanubrutinib) Approved in the U.S. for Chronic Lymphocytic Leukemia
BASEL, Switzerland& BEIJING& CAMBRIDGE, Mass. -- January 19, 2023 --(BUSINESS WIRE)-- BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 19, 2023 Category: Drugs & Pharmacology Source Type: news
FDA approves zanubrutinib for chronic lymphocytic leukemia or small lymphocytic lymphoma
On January 19, 2023, the Food and Drug Administration (FDA) approved zanubrutinib (Brukinsa, BeiGene USA, Inc.) for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 19, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Inflammation Linked to Inferior Outcomes in Leukemia
WEDNESDAY, Jan. 18, 2023 -- A unique inflammation signature, in which atypical B cells are identified, is associated with worse outcomes in patients with acute myeloid leukemia (AML), according to a study published online Jan. 11 in Nature... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 18, 2023 Category: Pharmaceuticals Source Type: news
Blood Test 24 Hours After Starting Chemo Predicts AML Survival Blood Test 24 Hours After Starting Chemo Predicts AML Survival
Protein changes in peripheral blood samples in the first 24 hours after starting chemotherapy could predict which patients with acute myeloid leukemia respond.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 18, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Doctors wrongly told me 10 times that my girl, 3, was fine... but she actually had leukaemia
Scottish tot Theano Zahorszki got the blood cancer leukaemia four months ago but NHS medics missed a potential early diagnosis by refusing to carry out blood tests, her family have claimed. (Source: the Mail online | Health)
Source: the Mail online | Health - January 17, 2023 Category: Consumer Health News Source Type: news
Congenital CMV Linked to Pediatric Hyperdiploid ALL Congenital CMV Linked to Pediatric Hyperdiploid ALL
Early congenital cytomegalovirus could be a modifiable risk factor for childhood hyperdiploid acute lymphoblastic leukemia but more research delineating a mechanism is warranted.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 13, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
AstraZeneca Withdraws Drug for Hairy Cell Leukemia From US Market AstraZeneca Withdraws Drug for Hairy Cell Leukemia From US Market
The company is planning to remove its leukemia drug moxetumomab pasudotox-tdfk (Lumoxiti) from the US market, saying there has been ' very low clinical uptake ' of the product.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 13, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
I'm celibate at 22 after cancer killed my sex drive
When Katie Mortimer, based in Cambridge, was diagnosed with leukaemia at 22, she didn't expect her to lose her sexual appetite completely. Now, she's embraced celibacy, she tells Metro.co.uk. (Source: the Mail online | Health)
Source: the Mail online | Health - January 10, 2023 Category: Consumer Health News Source Type: news
New Trials in Leukemia and Lymphoma: Could Your Patient Benefit? New Trials in Leukemia and Lymphoma: Could Your Patient Benefit?
Could one of your patients benefit from the latest clinical trials enrolling patients with leukemia or lymphoma?Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 9, 2023 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
FDA grants priority review to Roche ’s bispecific antibody glofitamab for people with relapsed or refractory large B-cell lymphoma
If approved,glofitamab would be the first fixed-duration CD20xCD3 T-cell engaging bispecific antibody approved to treat the most aggressive type of non-Hodgkin lymphomaResults from the pivotal phase I/II NP30179 study showedglofitamab induced durable response rates in people with heavily pre-treated large B-cell lymphoma, with 40% achieving a complete responseGlofitamab is part of Roche ’s industry-leading portfolio of T-cell engaging bispecific antibodies, which also includes the newly FDA-approved first-in-classLunsumio to treat follicular lymphomaBasel, 6 January 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announc...
Source: Roche Investor Update - January 6, 2023 Category: Pharmaceuticals Source Type: news
